News & Updates

Povidone iodine compares favourably with chlorhexidine gluconate in terms of reducing the incidence of surgical site infections (SSIs) after cardiac or abdominal surgical procedures, according to a study.

The use of a powder agent, either as monotherapy or in combination with other conventional therapy, appears to be safe and effective for endoscopic haemostasis in children with acute upper gastrointestinal (GI) bleeding (UGIB), according to real-world data from Singapore.

Dual glucagon-like peptide-1 (GLP-1) and glucagon (GCG) receptor agonism with cotadutide has shown a signal of benefit in the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis, according to the phase II PROXYMO trial.

The addition of a PARP inhibitor (PARPi), niraparib, to dostarlimab plus chemotherapy significantly improved progression-free survival (PFS) among patients with primary advanced or recurrent endometrial cancer, including those with mismatch repair proficient (MMRp)/microsatellite stable (MSS) tumours, according to results from part 2 of the RUBY trial presented at ESMO Gyn 2024.

The risks of ischaemic complications and bleeding are higher among patients with peripheral artery disease (PAD) who meet the frailty criteria after lower extremity revascularization in the VOYAGER PAD study. Regardless of frailty status, use of rivaroxaban lowers the ischaemic risk and increases bleeding.

The addition of arsenic trioxide (ATO) to all-trans retinoic acid (ATRA) with idarubicin significantly improves event-free survival (EFS) compared with ATRA plus chemotherapy (CHT) in the first-line setting for patients with newly diagnosed, high-risk acute promyelocytic leukaemia (APL), according to the APOLLO trial presented at EHA 2024.

During painful procedures, a virtual reality (VR) intervention appears to be as good as sedation in terms of alleviating pain and anxiety but is safer and associated with a shorter recovery period, according to a study.

Emodepside appears to be efficacious in the treatment of hookworm infections, with cure rates that surpass those achieved with albendazole but at the expense of increased adverse events (AEs), as shown in a phase IIb study.